Effects of Aerobic Versus Resistance Training on Bone Metabolism in Stage 3-4 Chronic Kidney Disease (NCT07133256) | Clinical Trial Compass
CompletedNot Applicable
Effects of Aerobic Versus Resistance Training on Bone Metabolism in Stage 3-4 Chronic Kidney Disease
Egypt60 participantsStarted 2025-01-01
Plain-language summary
This randomized controlled trial investigates the comparative effects of aerobic versus resistance training on bone mineral density (BMD) and bone metabolism markers in patients with stage 3 or 4 chronic kidney disease (CKD). The primary aim is to evaluate the impact of two distinct exercise modalities on serum osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), and the OPG/RANKL ratio, as well as densitometric changes at key skeletal sites.
Who can participate
Age range
30 Years – 50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 30 to 50 years
* Diagnosed with stage 3 or 4 chronic kidney disease (non-dialysis dependent)
* BMI between 20 and 24 kg/m²
* Not currently taking medications that affect bone density (e.g., corticosteroids, bisphosphonates)
* Non-smokers and abstinent from alcohol
* Not receiving hormone replacement therapy
* Willing and able to participate in supervised exercise sessions for 6 months
Exclusion Criteria:
* Diagnosis of type 1 diabetes mellitus
* Uncontrolled hypertension
* History of cardiovascular, musculoskeletal, endocrine, or metabolic bone disease
* Pregnant or planning pregnancy during the study period
* Participation in a structured exercise program within the last 3 months
* Contraindications to exercise as determined by medical evaluation
* Use of investigational drugs or enrollment in another clinical trial during the study period
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Serum Osteoprotegerin (OPG) and RANKL Concentrations
Timeframe: Baseline to 6 months post-intervention
2
Change in Bone Mineral Density (BMD)
Timeframe: Baseline to 6 months post-intervention
3
Change in OPG/RANKL Ratio
Timeframe: To assess the regulatory balance of bone remodeling. A higher OPG/RANKL ratio reflects reduced osteoclastic activity and improved bone metabolic status.